Key facts
- Alpheus Medical’s last known valuation is $140.0M (May 2025).
- It has raised $83.4M across 2 recorded rounds; the latest was Early Stage VC ($34.5M) in May 2025.
- Notable investors include OrbiMed, SV Health Investors, Samsara BioCapital, Revelation Partners, BrightEdge — 11 tracked in total.
- Alpheus Medical has filed 2 Form Ds with the SEC since 2022, most recently May 2025 ($34.5M sold to 22 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Alpheus Medical
Funding rounds
2 roundsAbout Alpheus Medical
Developer of a sonodynamic therapy device designed to treat solid tumors through non-invasive outpatient care. The company offers a drug-device combination activated by ultrasound, enabling individuals with recurrent glioblastoma multiforme to receive targeted therapy without imaging or inpatient admission.
- Sector
- Healthcare
- HQ
- Chanhassen, MN, United States
- Founded
- 2014
- Employees
- 9
- Website
- alpheusmedical.com/
- Ownership
- Privately Held (backing)
Alpheus Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alpheus Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alpheus Medical in its N-PORT filings yet. We sweep new filings monthly.